SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

JPMorgans bullish coverage, including its view that prediction markets could add growth optionality, is drawing attention to Genius Sports. Traders see the companys sports-data role as a potential beneficiary of prediction-market expansion, though legal uncertainty and the stocks volatility remain concerns.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp recent decline relative to other crypto assets is prompting questions about what is driving the selloff; traders speculate that large holders may be selling, but the cause is unconfirmed. The discussion also reflects lingering optimism around Compounds institutional push and limited token supply, alongside doubts about its performance and fundamentals.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

HSBCs upgrade of Synopsys has drawn attention, with traders discussing its shift toward royalty-based chip IP licensing and the potential for AI-enabled design tools to accelerate growth. Optimism over the business-model opportunity is tempered by skepticism that analyst calls alone can restore confidence, with investors looking for execution evidence at the upcoming investor day.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts Copilot overhaul, adding autonomous agents, coding tools and deeper Office integration, is driving attention and optimism about its enterprise AI opportunity. Traders debate whether the features can translate into meaningful adoption and revenue, while the sharp share move has also sparked contrasting breakout and pullback views.

OpenAI

OpenAIs confidential IPO filing is driving attention, with traders anticipating a major public listing while debating its timing and whether the companys high spending and valuation are justified. Some also worry that market volatility could delay the offering.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Discussion centers on Lillys position in the competitive GLP-1 and obesity-drug market, with traders weighing its portfolio and Foundayos progress against Novo and emerging rivals. The community also discusses a Nektar jury verdict and mixed technical signals, alongside bullish views on the business and concerns about share-price weakness and valuation.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Fords prolonged share-price slide is drawing attention, with traders citing weak sales and market-share pressureincluding expectations Hyundai could outsell Ford in Q3alongside uncertainty over tariffs and Chinese auto competition. The community is split between dip-buyers pointing to oversold conditions and bears expecting further weakness, with borrowing costs also raised as a concern.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs sharply higher August revenue and reports of tight advanced-node and packaging capacity are reinforcing the communitys view that AI-chip demand remains strong. Traders are mostly bullish on the demand outlook, while some point to valuation, market volatility and Taiwan-related risks.

Jersey Mike's Subs, Inc. engages in franchising fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, and craveable subs. The company was founded by Peter Cancro in 1956 and is headquartered in Tinton Falls, NJ.

Jersey Mike`s Subs Inc. - Ordinary Shares - Class A

JMKE is drawing attention after a steep post-IPO decline, with traders debating its valuation, debt burden, and the large share sales by existing owners in the offering. Some remain bullish on the franchises growth prospects and recent sales trends, while others see the stock as overpriced.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPM is drawing attention amid weakness in large-bank stocks, with traders pointing to rising Treasury yields and a flattening yield curve as potential pressure on net interest margins and credit conditions. The community is split between dip-buyers citing JPMs strength and technical support, and bearish traders concerned about a broader financial-sector downturn.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EyePoints DURAVYU missing the primary endpoint in its LUGANO Phase 3 trial has drawn attention to Oculars AXPAXLI, with traders viewing the result as easing competitive pressure and strengthening Oculars position in wet AMD. The community remains divided over whether AXPAXLIs trial results will translate into meaningful market adoption, alongside speculation about a potential buyout.

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

Equity

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. 

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.read more...

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.


Notable Wednesday Option Activity: OCUL, LLY, WEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ocular Therapeutix Inc (Symbol: OCUL), where a total of 25,374 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to ab...

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights

Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.


Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?

Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration therapy is expected to be submitted in the fourth quarter of 2026.

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1

Key PointsAcuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares...

What This Fund's $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key PointsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

Investors are speculating on a potential acquisition of the company to protect existing ophthalmic market shares and assets.

Traders are intensely analyzing trial efficacy results, specifically comparing clinical data against established industry benchmarks.

OCUL Ocular Therapeutix Inc